We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease

Xavier Roblin, MD; Jean Marc Phelip, MD, PhD
Arch Intern Med. 2008;168(6):667. doi:10.1001/archinte.168.6.667.
Text Size: A A A
Published online


Sorrentino et al1 report the results of infliximab with low-dose methotrexate for the prevention of postsurgical recurrence of ileocolonic Crohn disease (CD). The authors elected to coadminister methotrexate because it is known to reduce the long-term immunogenicity of infliximab.2 This is true only with episodic treatment with infliximab. Despite the observation that therapy with concomitant immunosuppressive agents reduces the development of antibodies against biological treatments, the authors have not significantly altered the response to infliximab3 in the treatment of CD when the agents are administered as an induction course followed by scheduled maintenance treatment. Recently, Maser et al4 demonstrated that the rate of clinical remission was higher for patients with a detectable trough serum concentration of infliximab compared with patients in whom serum infliximab was undetectable, including those without antibodies (82% vs 6%; P < .001). In this study, concurrent immunomodulators did not alter outcomes.4 A preliminary report from Van Assche et al5 suggested that the immunosuppressive therapy could be discontinued after 6 months with no effect on the loss of response to infliximab over 2 years. So the concept of combination immunosuppressive therapy needs to be discussed in light of the expanding reports of potential increases in severe infections and neoplasms.6

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles